Stocktoria
Gerresheimer AG GXI.DE
Gerresheimer AG (GXI.DE) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2024 revenue was €2.0B at a 5.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Healthcare · percentile among 79 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.002 |
| Retained earnings / assets | 0.196 |
| EBIT / assets | 0.061 |
| Equity / liabilities | 0.666 |
About Gerresheimer AG
Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization, and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors. The company also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, it offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. The company offers its products to pharmacy chains, supermarkets, and wholesalers. The company serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany.
FAQ
Is GXI.DE financially healthy?
Gerresheimer AG's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does GXI.DE pay a dividend?
No, Gerresheimer AG does not currently pay a dividend.
How profitable is GXI.DE?
In FY2024, Gerresheimer AG had a net margin of 5.4% and a return on equity of 7.3%.
Is GXI.DE overvalued or undervalued?
Gerresheimer AG trades at about 8.9× trailing earnings — below its 10-year norm (10-year range 20.5×–31.7×, median 27.1×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for GXI.DE?
The average Wall-Street price target for Gerresheimer AG is €23.37, about 17.4% below the recent price, from 11 analysts (consensus: hold).
Is GXI.DE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Gerresheimer AG: a Piotroski F-score of 5/9, an Altman Z″ in the grey zone, a P/E of about 8.9×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · DE · as of 2024-11-30. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.